An open-label, randomised, parallel clinical research evaluating the safety and efficacy of methotrexate and apremilast in patients with moderate to severe palm plantar psoriasis.
Abstract
Comparing apremilast to methotrexate, many studies have produced conflicting results onits efficacy and safety. Therefore, additional study is needed to determine how Apremilastworks in palmoplantar psoriasis.A randomised, prospective, parallel-group, open-label
study was conducted on patients with moderate to severe palmoplantar psoriasis. Theywere randomised to either the apremilast group (n = 22) or the methotrexate group (n =19) for a duration of 16 weeks. The main efficacy parameter was decreased scores on the
modified palmoplantar psoriasis severity index (mPPPASI) between weeks 0 and 16. Theproportion of patients who showed a dermatology life quality index decline of at least5àpoints from the start, the percentage of patients who achieved mPPPASI75 (75%
reduction in mPPPASI score), and the percentage of patients who obtained a StaticPhysician Global Assessment score of 0 (clear) or 1 (almost clear) were additionalmetrics.Although there was a substantial reduction from week 0 to week 16 within thegroup, there was no statistically significant difference in the drop in m-PPPASI scoresbetween the two groups at 16 weeks. The results of the secondary efficacy measures werethe same. Three people had abnormal liver function tests out of the twenty-four adverseevents reported in the methotrexate group. Two individuals had an upper respiratory tractinfection out of the 19 adverse events reported in the apremilast group.Apremilast is moretolerated than methotrexate when used to treat moderate to severe palmoplantarpsoriasis. Static Physician Global Assessment, Dermatology Life Quality Index,Palmoplantar Psoriasis, Palmoplantar Psoriasis Area and Severity Index, Apremilast.
References
Psoriasis. The New England Journal of Medicine 2009;361:496-509. Nestle FO, Kaplan DH, Barker J.
PB Nayak, BS Girisha, and TM Noronha. A research conducted in South India examined the relationship between the severity of psoriasis, family income, and quality of life. Journal of Indian Dermatology Online, 2018;9:165–9.
The authors of the study are Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, and colleagues. Results of a phase III randomized controlled study evaluating the effects of apremilast in psoriasis (ESTEEM 1) in patients with moderate to severe plaque psoriasis using the oral phosphodiesterase 4 (PDE4) inhibitor. The citation for the article is J Am AcadDermatol 2015;73:3749.
Miceli A, and Schmieder GJ; 4. Psoriasis around the palms and soles of the feet. Published by StatPearls in 2021, Treasure Island (FL) is a jeweler's paradise. You may access it at this link: https://www.ncbi.nlm.nih.gov/books/NBK448142/. [As of August 22, 2021].
Morrell DS, Sewell MJ, Burkhart CN. Dermatological pharmacology, Chapter 70. That instance, in Goodman and Gilman's The Pharmacological Basis of the Rapeutics. McGraw- Hill Education, 13th edition, page 1288.
The current authors include Bissonnette, Haydey, Rosoph, Lynde, Bukhalo, Fowler, and others. Apremilast as a therapy for moderate to severe palmoplantar psoriasis: Findings from a randomized, double-blind trial. J EurAcad The dermatologist published the article in 2018 with the DOI number 32: 403-10.
Psoriasis (Chapter 18), by Gudjonsson JE and Elder JT. Included in: Fitzpatrick's Dermatology in General Medicine. Book by McGraw-Hill Education. Pages 197–229.
S. Kt, V. Thakur, T. Narang, S. Dogra, and S. Handa 7. A randomized controlled study comparing the safety and effectiveness of methotrexate with apremilast in the treatment of palmoplantar psoriasis. Am J Clin Clinical dermatology 2021;22:415–23.
Shetty VH, Goel S, Babu AM, Eram H. Researchers compared the safety and effectiveness of oral methotrexate with that of oral apremilast in treating moderate to severe chronic plaque psoriasis.
Solaram M, Thomason D, Signorovitch JE, Betts KA, Armstrong AW. Efficacy and incremental cost per responder of methotrexate compared to apremilast for psoriasis patients who had never used methotrexate. "Journal of the American Academy of Dermatology" published in 2016 with the DOI 75:740–7406.
Brownasso AM, Salvini C, and Massone C. 11. An open-label pilot study with five patients evaluating efalizumab for severe palmo-plantar psoriasis. Journal of the European Academy of Dermatology and Venereology 2009;23:415–9.
The group consisting of Willismann‑Theis, Kromer, Gerdes, Linker, Magnolo, Sabat, and others. Aplatilost in palmoplantarpustulosis: an open-label research including many centers (APLANTUS). The citation for this article is J EurAcadDermatolVenereol 2021;35:204550.
Apremilast — A medication that helps with palmoplantar psoriasis, according to Parasramani SG and Pillai J. Ancient Egypt Journal of the American Academy of Dermatology and Venereology, 2021;41:103.
Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, and others. Results of a combined analysis from the phase II PSOR-005 and phase III ESTEEM clinical trials in patients with moderate to severe psoriasis regarding the use of apremilast, an oral phosphodiesterase-4 inhibitor, for the treatment of palmoplantar psoriasis. Journal of the American Academy of Dermatology 2016;75:99-105.
orses t. Diabetic palmoplantar eczema pustulosis: Existing therapies and potential outcomes in the future. I work The citation for the article is J Clin Dermatol 2016:17:349– 58.
Krueger GG and Feldman SR.. Clinical studies use psoriasis evaluation instruments. Annals of Rheumatology 2005;64 Suppl 2:i65–8.
Authors: Viswanathan HN, Chau D, Milmont CE, Yang W, Erondu N, Revicki DA, and others. When individuals with moderate to severe psoriasis achieve total skin clearance, their health-related quality of life improves and the intensity of their symptoms is decreased. Journal of the American Academy of Dermatology, Volume 26, Issue 9, 2015, pages 235-09.
REDITREXTM (Methotrexate), a drug approved by the FDA. This document may be accessed at: https://www.accessdata.fda.gov/drugsatfda_ docs/label/2019/210737s000lbl). **Last access**: August 12, 2022.
Maxtrex 10 mg Capsules. The Electronics Medicines Compendium. You may get this information at: https://www.medicines.org.uk/emc/product/1377/smpc. **Last access**: August 12, 2022.
OTEZLA (Apremilast), a drug approved by the FDA. This document may be accessed at this URL: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2017/205437s006lblPDF. **Last access**: August 12, 2022.
Otezla Film Coated Tablets, 30 mg. Electronics Medicines Compendium,
This information may be accessed at: https://www.medicines.org.uk/emc/product/3648/smpc. **Last access**: August 12, 2022.
